North America
-
Anti-Ebola drug and antibody show promise
The anti-Ebola drug remdesivir has shown major promise in a global clinical trial involved Covid-19 patients, it was announced last night. Read more
-
Could overactive immune cells contribute to Covid-19 deaths?
Medical researchers from across the globe are investigating if overactive immune cells that produce Neutrophil Extracellular Traps (NETs) cause the most severe Covid-19 cases. Read more
-
Pandemic set to worsen in Americas
The Covid-19 pandemic is yet to hit the Americas with "full force," a senior health official warned yesterday as the USA continued to report record numbers of deaths. Read more
-
Trials target care for critically ill Covid-19 patients
Two UK universities have embarked on a major clinical trial to study alternatives to ventilator care for patients critically ill with Covid-19. Read more
-
Backing for remdesivir and other breaking virus news
The anti-Ebola drug remdesivir is "highly effective" at halting the action of SARS-Cov-2 virus, according to new laboratory research. Read more
-
Hit and run’ features of coronavirus camouflage revealed
Fundamental features of the SARS-CoV-2 virus have been revealed for the first time by UK and USA scientists, it has been claimed. Read more
-
Raised Covid-19 risk for smokers and lung disease patients
Smokers and people with chronic obstructive pulmonary disease are at hugely increased risk of severe Covid-19 infection because of high levels of one enzyme, researchers warn today. Read more
-
MERS research points to Covid-19 vaccine
A new study is suggesting that an existing vaccine delivery approach could have potential against Covid-19. Read more
-
Plasma therapy shows promise – China
Plasma therapy from recovered patients has shown promise as a treatment for critically ill Covid-19 victims, Chinese doctors have reported. Read more
-
Promising’ COVID-19 vaccine revealed
A potential vaccine for COVID-19 has been described for the first time after promising mice studies, US scientists have revealed today (2 April 2020). Read more